BACKGROUND: Patients with hematologic malignancies can be successfully treated with donor lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell transplantation. The effect of donor lymphocyte infusion is mediated by donor T cells recognizing minor histocompatibility antigens. T cells recognizing hematopoietic restricted minor histocompatibility antigens may induce selective graft-versus-leukemia reactivity, whereas broadly-expressed antigens may be targeted in graft-versus-host disease. DESIGN AND METHODS: We analyzed in detail CD8(+) T-cell immunity in a patient with relapsed chronic myelogenous leukemia who responded to donor lymphocyte infusion with minimal graft-versus-host disease of the skin. CD8(+) T-cell clones specific for 4 HLA-B*40:01 restricted minor histocompatibility antigens were isolated which were identified by screening a plasmid cDNA library and whole genome association scanning. Detailed T-cell reactivity and monitoring experiments were performed to estimate the clinical and therapeutic relevance of the novel antigens. RESULTS: Three antigens were demonstrated to be expressed on primary leukemic cells of various origins as well as subtypes of non-malignant hematopoietic cells, whereas one antigen was selectively recognized on malignant hematopoietic cells with antigen presenting cell phenotype. Skin derived fibroblasts were only recognized after pre-treatment with IFN-γ by two T-cell clones. CONCLUSIONS: Our data show evidence for different roles of the HLA-B*40:01 restricted minor histocompatibility antigens in the onset and execution of the anti-tumor response. All antigens may have contributed to a graft-versus-leukemia effect, and one minor histocompatibility antigen (LB-SWAP70-1Q) has specific therapeutic value based on its in vivo immunodominance and strong presentation on leukemic cells of various origins, but absence of expression on cytokine-treated fibroblasts.
BACKGROUND:Patients with hematologic malignancies can be successfully treated with donor lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell transplantation. The effect of donor lymphocyte infusion is mediated by donor T cells recognizing minor histocompatibility antigens. T cells recognizing hematopoietic restricted minor histocompatibility antigens may induce selective graft-versus-leukemia reactivity, whereas broadly-expressed antigens may be targeted in graft-versus-host disease. DESIGN AND METHODS: We analyzed in detail CD8(+) T-cell immunity in a patient with relapsed chronic myelogenous leukemia who responded to donor lymphocyte infusion with minimal graft-versus-host disease of the skin. CD8(+) T-cell clones specific for 4 HLA-B*40:01 restricted minor histocompatibility antigens were isolated which were identified by screening a plasmid cDNA library and whole genome association scanning. Detailed T-cell reactivity and monitoring experiments were performed to estimate the clinical and therapeutic relevance of the novel antigens. RESULTS: Three antigens were demonstrated to be expressed on primary leukemic cells of various origins as well as subtypes of non-malignant hematopoietic cells, whereas one antigen was selectively recognized on malignant hematopoietic cells with antigen presenting cell phenotype. Skin derived fibroblasts were only recognized after pre-treatment with IFN-γ by two T-cell clones. CONCLUSIONS: Our data show evidence for different roles of the HLA-B*40:01 restricted minor histocompatibility antigens in the onset and execution of the anti-tumor response. All antigens may have contributed to a graft-versus-leukemia effect, and one minor histocompatibility antigen (LB-SWAP70-1Q) has specific therapeutic value based on its in vivo immunodominance and strong presentation on leukemic cells of various origins, but absence of expression on cytokine-treated fibroblasts.
Authors: Cornelis A M Van Bergen; Caroline E Rutten; Edith D Van Der Meijden; Simone A P Van Luxemburg-Heijs; Ellie G A Lurvink; Jeanine J Houwing-Duistermaat; Michel G D Kester; Arend Mulder; Roel Willemze; J H Frederik Falkenburg; Marieke Griffioen Journal: Cancer Res Date: 2010-11-09 Impact factor: 12.701
Authors: W A Erik Marijt; Mirjam H M Heemskerk; Freke M Kloosterboer; Els Goulmy; Michel G D Kester; Menno A W G van der Hoorn; Simone A P van Luxemburg-Heys; Manja Hoogeboom; Tuna Mutis; Jan Wouter Drijfhout; Jon J van Rood; Roel Willemze; J H Frederik Falkenburg Journal: Proc Natl Acad Sci U S A Date: 2003-02-24 Impact factor: 11.205
Authors: F M Kloosterboer; S A P van Luxemburg-Heijs; R A van Soest; A M Barbui; H M van Egmond; M P W Strijbosch; M G D Kester; W A F Marijt; E Goulmy; R Willemze; J H F Falkenburg Journal: Leukemia Date: 2004-04 Impact factor: 11.528
Authors: Edus H Warren; Nobuharu Fujii; Yoshiki Akatsuka; Colette N Chaney; Jeffrey K Mito; Keith R Loeb; Ted A Gooley; Michele L Brown; Kevin K W Koo; Kellie V Rosinski; Seishi Ogawa; Aiko Matsubara; Frederick R Appelbaum; Stanley R Riddell Journal: Blood Date: 2010-01-13 Impact factor: 22.113
Authors: Anita N Stumpf; Edith D van der Meijden; Cornelis A M van Bergen; Roel Willemze; J H Frederik Falkenburg; Marieke Griffioen Journal: Blood Date: 2009-08-25 Impact factor: 22.113
Authors: Margot J Pont; Willemijn Hobo; Maria W Honders; Simone A P van Luxemburg-Heijs; Michel G D Kester; Annemarie M van Oeveren-Rietdijk; Nicolaas Schaap; Hetty C de Boer; Cornelis A M van Bergen; Harry Dolstra; J H Frederik Falkenburg; Marieke Griffioen Journal: Haematologica Date: 2015-06-11 Impact factor: 9.941
Authors: Cornelis A M van Bergen; Simone A P van Luxemburg-Heijs; Liesbeth C de Wreede; Matthijs Eefting; Peter A von dem Borne; Peter van Balen; Mirjam H M Heemskerk; Arend Mulder; Fransiscus H J Claas; Marcelo A Navarrete; Wilhelmina M Honders; Caroline E Rutten; Hendrik Veelken; Inge Jedema; Constantijn J M Halkes; Marieke Griffioen; J H Frederik Falkenburg Journal: J Clin Invest Date: 2017-01-09 Impact factor: 14.808
Authors: Rimke Oostvogels; Henk M Lokhorst; Monique C Minnema; Maureen van Elk; Kelly van den Oudenalder; Eric Spierings; Tuna Mutis; Robbert M Spaapen Journal: Haematologica Date: 2014-08-22 Impact factor: 9.941
Authors: Wei Wang; Hu Huang; Michael Halagan; Cynthia Vierra-Green; Michael Heuer; Jason E Brelsford; Michael Haagenson; Richard H Scheuermann; Amalio Telenti; William Biggs; Nathaniel M Pearson; Julia Udell; Stephen Spellman; Martin Maiers; Caleb J Kennedy Journal: Blood Adv Date: 2018-10-09
Authors: Juliana K Sampson; Nihar U Sheth; Vishal N Koparde; Allison F Scalora; Myrna G Serrano; Vladimir Lee; Catherine H Roberts; Max Jameson-Lee; Andrea Ferreira-Gonzalez; Masoud H Manjili; Gregory A Buck; Michael C Neale; Amir A Toor Journal: Br J Haematol Date: 2014-04-18 Impact factor: 6.998
Authors: Edus H Warren; Xinyi Cindy Zhang; Shuying Li; Wenhong Fan; Barry E Storer; Jason W Chien; Michael J Boeckh; Lue Ping Zhao; Paul J Martin; John A Hansen Journal: Blood Date: 2012-08-02 Impact factor: 22.113
Authors: Marlieke L M Jongsma; Antonius A de Waard; Matthijs Raaben; Tao Zhang; Birol Cabukusta; René Platzer; Vincent A Blomen; Anastasia Xagara; Tamara Verkerk; Sophie Bliss; Xiangrui Kong; Carolin Gerke; Lennert Janssen; Elmer Stickel; Stephanie Holst; Rosina Plomp; Arend Mulder; Soldano Ferrone; Frans H J Claas; Mirjam H M Heemskerk; Marieke Griffioen; Anne Halenius; Hermen Overkleeft; Johannes B Huppa; Manfred Wuhrer; Thijn R Brummelkamp; Jacques Neefjes; Robbert M Spaapen Journal: Immunity Date: 2020-12-02 Impact factor: 31.745